Medizone International (MZEIQ) 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 31, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Medizone International Inc
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		369,934,068
Amendment Flag	false
Entity Central Index Key	753,772
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2016	Dec. 31, 2015	[1]
Current Assets:
Cash	$ 49,288	$ 745,078
Inventory	323,118	277,823
Prepaid expenses	34,619	31,986
Total Current Assets	407,025	1,054,887
Property and equipment, net	208	415
Other Assets:
Trademark and patents, net	159,045	176,086
Lease deposit	4,272	4,272
Total Other Assets	163,317	180,358
Total Assets	570,550	1,235,660
Current Liabilities:
Accounts payable	433,826	491,044
Accounts payable – related parties	228,109	233,109
Accrued expenses	600,362	554,834
Accrued expenses – related parties	1,928,659	1,928,659
Customer deposits	118,500	0
Other payables	224,852	224,852
Notes payable	292,124	297,396
Total Current Liabilities	3,826,432	3,729,894
Notes payable, net of current portion	75,000	75,000
Total liabilities	3,901,432	3,804,894
Stockholders’ Deficit:
Preferred stock, $0.00001 par value: 50,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value: 395,000,000 shares authorized; 369,934,068 and 369,434,068 shares outstanding, respectively	369,934	369,434
Additional paid-in capital	32,544,146	32,496,646
Accumulated other comprehensive loss	(38,454)	(36,968)
Accumulated deficit	(36,206,508)	(35,398,346)
Total Stockholders’ Deficit	(3,330,882)	(2,569,234)
Total Liabilities and Stockholders’ Deficit	$ 570,550	$ 1,235,660
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been prepared using information from the audited consolidated balance sheet as of that date.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2016	Dec. 31, 2015	[1]
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	395,000,000	395,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares outstanding	369,934,068	369,434,068
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been prepared using information from the audited consolidated balance sheet as of that date.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenues	$ 0	$ 0	$ 0	$ 0
Operating Expenses:
Cost of revenues	0	0	0	0
General and administrative	216,182	288,182	495,246	601,014
Research and development	82,075	76,840	268,036	154,073
Depreciation and amortization	13,988	13,273	27,814	26,303
Total Operating Expenses	312,245	378,295	791,096	781,390
Loss from Operations	(312,245)	(378,295)	(791,096)	(781,390)
Interest expense	(8,539)	(6,222)	(17,130)	(12,618)
Interest income	11	0	64	0
Net Loss	(320,773)	(384,517)	(808,162)	(794,008)
Other comprehensive (loss) gain on foreign currency translation	(2,381)	1,431	(1,486)	19,662
Total Comprehensive Loss	$ (323,154)	$ (383,086)	$ (809,648)	$ (774,346)
Basic and Diluted Net Loss per Common Share (in Dollars per share)	$ 0	$ 0	$ 0	$ 0
Weighted Average Number of Common Shares Outstanding (in Shares)	369,934,068	351,692,310	369,920,332	349,488,212

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016		Jun. 30, 2015
Cash Flows from Operating Activities:
Net loss	$ (808,162)		$ (794,008)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	27,814		26,303
Stock-based compensation expense	48,000		126,369
Changes in operating assets and liabilities:
Prepaid expenses	28,867		42,077
Inventory	(45,295)		0
Accounts payable and accounts payable – related parties	(62,218)		66,423
Accrued expenses and accrued expenses – related parties	45,527		40,037
Customer deposits	118,500		0
Net Cash Used in Operating Activities	(646,967)		(492,799)
Cash Flows from Investing Activities:
Cost of registering patents	(10,565)		(12,932)
Net Cash Used in Investing Activities	(10,565)		(12,932)
Cash Flows from Financing Activities:
Principal payments on notes payable	(36,772)		(37,274)
Issuance of common stock for cash	0		546,000
Net Cash (Used in) Provided by Financing Activities	(36,772)		508,726
Effect of Foreign Currency Exchange Rates	(1,486)		19,662
Net (decrease) increase in cash	(695,790)		22,657
Cash as of beginning of the period	745,078	[1]	140,496
Cash as of end of the period	49,288		163,153
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	3,568		725
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Financing of insurance policies	$ 31,500		$ 37,392
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been prepared using information from the audited consolidated balance sheet as of that date.

NOTE 1 BASIS OF PRESENTATION

NOTE 1 BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2016
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	NOTE 1 BASIS OF PRESENTATION The financial information of Medizone International, Inc., a Nevada corporation (the “Company”) included herein is unaudited and has been prepared consistent with U.S. generally accepted accounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all information and notes required by US GAAP for complete financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2015. In the opinion of management, these financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are necessary in the opinion of management for a fair presentation of results for the interim periods presented. The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the full year ending December 31, 2016.

NOTE 2 CANADIAN FOUNDATION FOR

NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH	6 Months Ended
	Jun. 30, 2016
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible. Accounting standards require a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the VIE’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the VIE. In addition, a legal entity may be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate its financial statements with those of the VIE. The Company determined that CFGH met the requirements of a VIE effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial statements of CFGH have been consolidated with those of the Company for all periods presented.

NOTE 3 BASIC AND DILUTED NET LO

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: For the Three Months Ended June 30, 2016 2015 Numerator: Net loss $ (320,773 ) $ (384,517 ) Denominator: Weighted average number of common shares outstanding 369,934,068 351,692,310 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) For the Six Months Ended June 30, 2016 2015 Numerator: Net loss $ (808,162 ) $ (794,008 ) Denominator: Weighted average number of common shares outstanding 369,920,332 349,488,212 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) Common stock equivalents, consisting of options to purchase 20,865,000 shares, have not been included in the calculation as their effect is antidilutive for the periods presented.

NOTE 4 GOING CONCERN

NOTE 4 GOING CONCERN	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 4 GOING CONCERN The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred significant losses from its inception through June 30, 2016, which have resulted in an accumulated deficit of $36,206,508 as of June 30, 2016. The Company does not have funds sufficient to cover its operating costs for the next 12 months, has negative equity, and has a working capital deficit of $3,419,407 as of June 30, 2016. The Company has relied exclusively on debt and equity financing to sustain its operations. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern. Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company’s attaining profitable operations. The Company will require substantial additional funds to complete the continued development of its products and product manufacturing, and to fund expected additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the necessary additional funding, it will be forced to substantially reduce or cease operations. The Company believes that it will need approximately $1,500,000 over the next 12 months for continued production manufacturing and related activities, research, development, and marketing activities, as well as for general corporate purposes. No cash was generated through the sale of shares of common stock for the quarter ended June 30, 2016. The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

NOTE 5 COMMITMENTS AND CONTINGE

NOTE 5 COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 5 COMMITMENTS AND CONTINGENCIES The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows. Litigation Rakas vs. Medizone International, Inc Other Payables As of June 30, 2016 and December 31, 2015, the Company has $224,852 of past due payables for which the Company has not received statements or demands for payment for over 10 years. Although management of the Company does not believe that the amounts will be required to be paid, the amounts are recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired. Operating Leases The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform. The lease term is month-to-month with a monthly lease payment of $1,537 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”). Leases for a second laboratory space for full scale room testing and a storage unit are on a month-to-month basis with monthly lease payments of CD$1,537 and CD$475, respectively, plus the applicable GST. The Company has a non-cancelable lease for office space located in California, with monthly payments of approximately $2,400 through December 31, 2016.

NOTE 6 COMMON STOCK OPTIONS

NOTE 6 COMMON STOCK OPTIONS	6 Months Ended
	Jun. 30, 2016
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 6 COMMON STOCK OPTIONS In August 2013, the Company granted options for the purchase of 250,000 shares of common stock to a consultant, of which 50,000 were immediately vested. These options are exercisable at $0.10 per share for five years from the date of grant with 50,000 options vesting immediately and the other 200,000 options vesting upon the achievement of certain milestones, which were met in 2015. The Company recognized expense of $17,659 during the six months ended June 30, 2015, as milestones were achieved for the remaining 200,000 options. On February 26, 2014, the Company granted to a new director options for the purchase of 2,000,000 shares of common stock, with an exercise price of $0.1095 per share. Of these options, 1,000,000 vested on February 26, 2015 and the remaining 1,000,000 options will vest upon the successful achievement of certain milestones. Unvested options vest immediately in the event of a change in control of the Company. The options are exercisable for five years from the date of grant. The Company recognized $16,017 of expense in connection with these options during the six months ended June 30, 2015. The Company will measure and begin recognizing the remaining expense when the achievement of the required milestones becomes probable. On February 26, 2014, the Company granted options to six consultants and service providers for the purchase of a total of 250,000 shares of common stock at an exercise price of $0.1095 per share. Options for 200,000 shares vested immediately upon grant and options for the remaining 50,000 shares vested January 9, 2015. The options are exercisable for five years from the date of grant. The grant date fair value of these options was $24,023. The Company recognized expense of $800 in connection with these options during the six months ended June 30, 2015. On May 6, 2014, the Company granted options to a consultant for the purchase of 100,000 shares of common stock at an exercise price of $0.19 per share. Options for 50,000 shares vested immediately upon grant and options for the remaining 50,000 shares vested during the six months ended June 30, 2015, when certain milestones were achieved. The options are exercisable for five years from the date of grant. The Company recognized expense of $8,342 in connection with these options during the six months ended June 30, 2015. On August 15, 2014, the Company granted options to a consultant for the purchase of 75,000 shares of common stock at an exercise price of $0.13 per share. The shares will vest when certain required milestones are achieved. The options are exercisable for five years from the date of grant. The Company will measure and begin recognizing expense when the achievement of the required milestones becomes probable. On October 7, 2014, the Company granted to a new board member options for the purchase of 1,000,000 shares of common stock, with an exercise price of $0.16 per share. These options were fully vested on October 7, 2015. The options are exercisable for five years. The grant date fair value of the options was $140,178. The Company recognized $70,088 of expense in connection with these options during the six months ended June 30, 2015 respectively. On December 4, 2014, the Company granted options to four consultants for the purchase of 140,000 shares of common stock at an exercise price of $0.11 per share. The options are fully vested and are exercisable for five years from the date of grant. The Company recognized expense of $13,461 during the six months ended June 30, 2015. In August 2015, the Company granted options for the purchase of a total of 7,150,000 shares of common stock for services rendered, as follows: 6,000,000 shares total to five directors of the Company, 650,000 shares total to four consultants, and 500,000 shares to an employee of the Company. All options vested upon grant, have an exercise price of $0.088 per share, and are exercisable for up to five years from the date of grant. The aggregate fair value of these options at the date of grant was $541,687, which the Company recognized as expense during the year ended December 31, 2015. In August 2015, the Company granted options to a consultant for the purchase of a total of 250,000 shares of common stock at an exercise price of $0.085 per share. These options vested upon grant and are exercisable for up to five years. The aggregate fair value of these options at the date of grant was $18,991, which the Company recognized as expense during the year ended December 31, 2015. On May 19, 2016, the Company granted options to an employee for the purchase of 150,000 shares of common stock at an exercise price of $0.05 per share. The fair value of these options on the date of grant was $6,461. The shares will vest at the earlier of 18 months of service or when certain milestones are achieved, and are exercisable for five years from the date of grant. The Company is recognizing the expense ratably over the 18-months service period. The Company did not recognize expense during the 6 months ended June 30, 2016 as it was not material to the fair presentation of the consolidated financial statements. The Company estimates the fair value of each stock option award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Expense of $0 and $126,369 related to stock options was recorded for the six months ended June 30, 2016 and 2015, respectively. Excluding options whose performance condition is not yet deemed probable, as of June 30, 2016, the Company had unvested outstanding options with related unrecognized expense of $112,147. The Company will recognize this expense over the service period or when the achievement of the required milestones becomes probable. The Company estimated the fair value of the stock options described in the above paragraphs as of the date of the grant or date of re-measurement, based on the following weighted-average assumptions: Risk-free interest rate 1.50% to 1.69 % Expected life 5 years Expected volatility 130.31% to 136.34 % Dividend yield 0.00 % A summary of the status of the Company’s outstanding options as of June 30, 2016 and changes during the six months then ended, is presented below: Shares Weighted Average Exercise Price Outstanding, beginning of the period 20,965,000 $ 0.145 Granted 150,000 - Expired/Canceled (250,000 ) 0.002 Exercised - - Outstanding, end of the period 20,865,000 0.143 Exercisable 19,640,000 0.145

NOTE 7 STOCK TRANSACTIONS AND S

NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS During January 2016, the Company issued 500,000 restricted shares of common stock to a consultant. The fair value of the shares on the date of grant was $48,000, or $0.096 per share. The Company recorded compensation expense of $48,000 in connection with the issuance of the shares. During April, May, and June 2015 the Company sold an aggregate of 7,500,000 restricted shares of common stock to eight accredited investors for cash proceeds totaling $375,000, or $0.05 per share. During February and March 2015, the Company sold an aggregate of 3,000,000 restricted shares of common stock to seven accredited investors for cash proceeds totaling $150,000, or $0.05 per share. During February 2015, the Company sold 300,000 restricted shares of common stock to an accredited investor for cash proceeds totaling $21,000, or $0.07 per share.

NOTE 8 ACCOUNTS PAYABLE - RELAT

NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 ACCOUNTS PAYABLE – RELATED PARTIES As of June 30, 2016 and December 31, 2015, the Company owed $228,109 and $233,109, respectively, to certain consultants for services. These consultants are stockholders of the Company and are related parties.

NOTE 9 RECENT ACCOUNTING PRONOU

NOTE 9 RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 9 RECENT ACCOUNTING PRONOUNCEMENTS In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) In February 2016, the FASB released ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share- Based Payment Accounting In April 2015, the FASB issued ASU No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30), Simplifying the Presentation of Debt Issuance Costs.

NOTE 10 SUBSEQUENT EVENTS

NOTE 10 SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 10 SUBSEQUENT EVENTS The Company has evaluated subsequent events through the filing date of this Quarterly Report on Form 10-Q and noted none that require accounting or disclosure in the accompanying financial statements.

NOTE 3 BASIC AND DILUTED NET 16

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows: For the Three Months Ended June 30, 2016 2015 Numerator: Net loss $ (320,773 ) $ (384,517 ) Denominator: Weighted average number of common shares outstanding 369,934,068 351,692,310 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 ) For the Six Months Ended June 30, 2016 2015 Numerator: Net loss $ (808,162 ) $ (794,008 ) Denominator: Weighted average number of common shares outstanding 369,920,332 349,488,212 Basic and diluted net loss per common share $ (0.00 ) $ (0.00 )

NOTE 6 COMMON STOCK OPTIONS (Ta

NOTE 6 COMMON STOCK OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The Company estimated the fair value of the stock options described in the above paragraphs as of the date of the grant or date of re-measurement, based on the following weighted-average assumptions: Risk-free interest rate 1.50% to 1.69 % Expected life 5 years Expected volatility 130.31% to 136.34 % Dividend yield 0.00 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the status of the Company’s outstanding options as of June 30, 2016 and changes during the six months then ended, is presented below: Shares Weighted Average Exercise Price Outstanding, beginning of the period 20,965,000 $ 0.145 Granted 150,000 - Expired/Canceled (250,000 ) 0.002 Exercised - - Outstanding, end of the period 20,865,000 0.143 Exercisable 19,640,000 0.145

NOTE 2 CANADIAN FOUNDATION FO18

NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH (Details)	12 Months Ended
	Dec. 31, 2008
Disclosure Text Block [Abstract]
Variable Interest Entity, Qualitative or Quantitative Information, Purpose of VIE	(1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible.

NOTE 3 BASIC AND DILUTED NET 19

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details)	6 Months Ended
	Jun. 30, 2016shares
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,865,000

NOTE 3 BASIC AND DILUTED NE

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Schedule of Earnings Per Share, Basic and Diluted [Abstract]
Numerator: Net loss	$ (320,773)	$ (384,517)	$ (808,162)	$ (794,008)
Denominator: Weighted average number of common shares outstanding	369,934,068	351,692,310	369,920,332	349,488,212
Basic and diluted net loss per common share	$ 0	$ 0	$ 0	$ 0

NOTE 4 GOING CONCERN (Details)

NOTE 4 GOING CONCERN (Details) - USD ($)	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	[1]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained Earnings (Accumulated Deficit)	$ (36,206,508)	$ (35,398,346)
Working capital (deficit)	$ (3,419,407)
Substantial Doubt about Going Concern, Conditions or Events	The Company believes that it will need approximately $1,500,000 over the next 12 months for continued production manufacturing and related activities, research, development, and marketing activities, as well as for general corporate purposes.
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been prepared using information from the audited consolidated balance sheet as of that date.

NOTE 5 COMMITMENTS AND CONTIN22

NOTE 5 COMMITMENTS AND CONTINGENCIES (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2016CAD	Dec. 31, 2002USD ($)	Dec. 31, 2001USD ($)	Dec. 31, 2015USD ($)
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Accounts Payable, Current	$ 433,826				$ 491,044	[1]
Accounts Payable, Other, Current	224,852				224,852	[1]
Default Judgement [Member] | Rakas Litigation [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Accounts Payable, Current	143,000				143,000
Litigation Fees [Member] | Rakas Litigation [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Accounts Payable, Current	21,308				$ 21,308
Settlement Amount, September 2001 [Member] | Rakas Litigation [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Litigation Settlement, Amount				$ 25,000
Settlement Amount, January 2002 [Member] | Default Judgement [Member] | Rakas Litigation [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Sought, Value			$ 143,000
Building [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	$ 2,400
Building [Member] | Certified Laboratory Space [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals | CAD		CAD 1,537
Building [Member] | Second Laboratory for Full Scale Room Testing [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals | CAD		1,537
Building [Member] | Full Scale Room Testing [Member]
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals | CAD		CAD 475
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been prepared using information from the audited consolidated balance sheet as of that date.

NOTE 6 COMMON STOCK OPTIONS (De

NOTE 6 COMMON STOCK OPTIONS (Details)	May 19, 2016USD ($)$ / sharesshares	Dec. 04, 2014$ / sharesshares	Oct. 07, 2014USD ($)$ / sharesshares	Aug. 15, 2014$ / sharesshares	May 06, 2014$ / sharesshares	Feb. 26, 2014USD ($)$ / sharesshares	Aug. 31, 2015$ / sharesshares	Aug. 31, 2013$ / sharesshares	Jun. 30, 2016USD ($)shares	Jun. 30, 2015USD ($)shares	Dec. 31, 2015USD ($)
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	150,000								150,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares	$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	5 years
Share-based Compensation (in Dollars) | $	$ 6,461								$ 48,000	$ 126,369
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	18 months
August 2015 [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							7,150,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years
Share-based Compensation (in Dollars) | $											$ 541,687
Director [Member] | October 7, 2014 [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,000,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares			$ 0.16
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			5 years
Share-based Compensation (in Dollars) | $										70,088
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars) | $			$ 140,178
Non-Employee Stock Option [Member] | August 2013 [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								250,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares								$ 0.10
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								5 years
Share-based Compensation (in Dollars) | $										$ 17,659
Non-Employee Stock Option [Member] | August 2013 [Member] | Share-based Compensation Award, Tranche One [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								50,000
Non-Employee Stock Option [Member] | August 2013 [Member] | Share-based Compensation Award, Tranche Two [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								200,000
Non-Employee Stock Option [Member] | February 2014 [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						250,000				800
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares						$ 0.1095
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						5 years
Number of consultants and service providers issued options						6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars) | $						$ 24,023
Non-Employee Stock Option [Member] | February 2014 [Member] | Share-based Compensation Award, Tranche One [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						200,000
Non-Employee Stock Option [Member] | February 2014 [Member] | Share-based Compensation Award, Tranche Two [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						50,000
Non-Employee Stock Option [Member] | May 6, 2014 [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					100,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares					$ 0.19
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					5 years
Share-based Compensation (in Dollars) | $										$ 8,342
Non-Employee Stock Option [Member] | May 6, 2014 [Member] | Share-based Compensation Award, Tranche One [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					50,000
Non-Employee Stock Option [Member] | May 6, 2014 [Member] | Share-based Compensation Award, Tranche Two [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					50,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					vested immediately upon grant and options for the remaining 50,000 shares vested during the six months ended June 30, 2015, when certain milestones were achieved.
Non-Employee Stock Option [Member] | August 15, 2014 [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				75,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares				$ 0.13
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				5 years
Non-Employee Stock Option [Member] | December 4, 2014 [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		140,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares		$ 0.11
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		5 years
Share-based Compensation (in Dollars) | $										13,461
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		The shares will vest when certain required milestones are achieved.
Number of consultants and service providers issued options		4
Non-Employee Stock Option [Member] | August 2015 [Member] | Options Granted for Consulting Services [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							250,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares							$ 0.085
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years
Share-based Compensation (in Dollars) | $											$ 18,991
Non-Employee Stock Option [Member] | August 2015 [Member] | Options Granted to Four Consultants [Member[
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							650,000
Number of consultants and service providers issued options							4
Employee Stock Option [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation (in Dollars) | $									0	126,369
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | $									$ 112,147
Employee Stock Option [Member] | August 2015 [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							500,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares							$ 0.088
Employee Stock Option [Member] | Director [Member] | February 2014 [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						2,000,000
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $ / shares						$ 0.1095
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						5 years
Share-based Compensation (in Dollars) | $										$ 16,017
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						Unvested options vest immediately in the event of a change in control of the Company
Employee Stock Option [Member] | Director [Member] | February 2014 [Member] | Share-based Compensation Award, Tranche One [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						1,000,000
Employee Stock Option [Member] | Director [Member] | February 2014 [Member] | Share-based Compensation Award, Tranche Two [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						vest upon the successful achievement of certain milestones
Employee Stock Option [Member] | Director [Member] | August 2015 [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							6,000,000
Number of directors issued options							5

NOTE 6 COMMON STOCK OPTIONS

NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options	6 Months Ended
	Jun. 30, 2016
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items]
Expected life	5 years
Dividend yield	0.00%
Minimum [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items]
Risk-free interest rate	1.50%
Expected volatility	130.31%
Maximum [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items]
Risk-free interest rate	1.69%
Expected volatility	136.34%

NOTE 6 COMMON STOCK OPTIO25

NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity - $ / shares	May 19, 2016	Jun. 30, 2016
Schedule of Share-Based Compensation, Stock Options, Activity [Abstract]
Outstanding, beginning of the period		20,965,000
Outstanding, beginning of the period		$ 0.145
Granted	150,000	150,000
Granted		$ 0
Expired/Canceled		(250,000)
Expired/Canceled		$ 0.002
Exercised		0
Exercised		$ 0
Outstanding, end of the period		20,865,000
Outstanding, end of the period		$ 0.143
Exercisable		19,640,000
Exercisable		$ 0.145

NOTE 7 STOCK TRANSACTIONS AND26

NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details)	May 19, 2016USD ($)	Jan. 31, 2016USD ($)$ / sharesshares	Feb. 28, 2015USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)$ / shares
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items]
Share-based Compensation	$ 6,461					$ 48,000	$ 126,369
Stock Issued During Period, Shares, New Issues (in Shares) | shares					7,500,000
Number of Investors					8
Proceeds from Issuance or Sale of Equity					$ 375,000
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares					$ 0.05		$ 0.05
Restricted Stock [Member]
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares) | shares		500,000
Stock Issued During Period, Value, Issued for Services		$ 48,000
Shares Issued, Price Per Share (in Dollars per share) | $ / shares		$ 0.096
Share-based Compensation		$ 48,000
Stock Issued During Period, Shares, New Issues (in Shares) | shares			300,000	3,000,000
Number of Investors				7
Proceeds from Issuance or Sale of Equity				$ 150,000
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares			$ 0.07	$ 0.05
Stock Issued During Period, Value, New Issues			$ 21,000

NOTE 8 ACCOUNTS PAYABLE - REL27

NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Related Party Transactions [Abstract]
Accounts Payable, Related Parties, Current	$ 228,109	$ 233,109	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2015 has been prepared using information from the audited consolidated balance sheet as of that date.